Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M55,784Revenue $M3,396Net Margin (%)13.6Altman Z-Score29.7
Enterprise Value $M55,568EPS $4.0Operating Margin %31.2Piotroski F-Score4
P/E(ttm)134Beneish M-Score-2.0Pre-tax Margin (%)29.5Higher ROA y-yN
Price/Book16.710-y EBITDA Growth Rate %--Quick Ratio3.5Cash flow > EarningsY
Price/Sales18.15-y EBITDA Growth Rate %--Current Ratio3.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %14.4ROA % (ttm)11.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)16.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M103ROIC % (ttm)20.2Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2015-06-30 Reduce-0.15%$438.27 - $539.4
($487.44)
$ 538.0010%Reduce 5.36%2,764,540
REGNRon Baron 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 538.0010%Reduce 0.15%7,479
REGNMario Gabelli 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 538.0010%Reduce 2.05%2,145
REGNKen Fisher 2015-06-30 Add$438.27 - $539.4
($487.44)
$ 538.0010%Add 5.81%565
REGNKen Fisher 2015-03-31 Add$396.89 - $488.87
($423.8)
$ 538.0027%Add 1.91%534
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 538.0037%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 538.0037%Sold Out0
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 538.0060%New holding583
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 538.0060%Add 60.05%1,410
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 538.0081%Add 60.34%2,795,500
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 538.0081%New holding2,295
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 538.0081%New holding881
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 538.0076%Add 23.47%1,743,468
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 538.0075%New holding6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 538.0087%Sold Out0
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 538.00105%New holding3,285
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 538.00213%Add 170.41%1,412,100
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 538.00298%Reduce 24.56%522,200
REGNDodge & Cox 2012-03-31 Sold Out $57.83 - $119.96
($92.23)
$ 538.00483%Sold Out0
REGNCarl Icahn 2011-09-30 Sold Out -1.76%$44.96 - $72.19
($58.66)
$ 538.00817%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Powchik PeterSVP Clinical Development & Reg 2015-08-14Sell23,485$573.38-6.17view
POON CHRISTINE ADirector 2015-08-12Sell112$564.16-4.64view
GILMAN ALFRED GDirector 2015-08-06Sell5,000$587.12-8.37view
Terifay Robert JSVP Commercial 2015-08-06Sell13,423$588.97-8.65view
Van Plew Daniel PSVP & General Mgr Industrial O 2015-08-06Sell4,028$584.36-7.93view
McCorkle Douglas SVP Controller and Asst Treasur 2015-08-05Sell5,000$585.53-8.12view
Tessier-Lavigne MarcDirector 2015-08-05Sell5,000$590.26-8.85view
Landry Robert ESVP Finance & CFO 2015-08-05Sell4,000$592.84-9.25view
GOLDSTEIN JOSEPH LDirector 2015-08-04Sell2,000$586-8.19view
Sanofi10% Owner 2015-07-27Buy10,639$537.480.1view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 
Weekly Insider Sells Highlights: FB, AET, REGN, TYC Aug 18 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
1 Feb 23 2015 
1 Feb 23 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 

More From Other Websites
Time to Buy Amgen After Newly Approved Drug? Aug 28 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
Amgen's Repatha OK'd With Similar Label To Praluent Aug 27 2015
FDA approves Amgen's cholesterol drug Repatha Aug 27 2015
Cholesterol drug wars Aug 27 2015
Regeneron Pharmaceuticals (REGN) Stock Is the 'Chart of the Day' Aug 27 2015
'We See Opportunity in Biogen, Gilead and Regeneron,' Morgan Stanley Says Aug 27 2015
Cholesterol drug wars: Amgen Aug 27 2015
Stocks: Don't Kill Your Darlings Aug 25 2015
9 Stocks Strong Enough To Weather This Storm Aug 25 2015
IBB ETF Pounded by Biotech and Pharma Subgroups in Early August Aug 25 2015
What Are IBB and XBI’s Valuations? Aug 25 2015
4 Stocks to Sell Now, Until the Fed Acts Aug 25 2015
A Buying Opportunity For Regeneron: RBC Aug 24 2015
4 Reasons To Keep An Eye On Biotech Stock Celgene Aug 21 2015
Dividend cuts for big oil? Aug 20 2015
Cholesterol war heats up Aug 20 2015
3 ways to play biotech's beatdown Aug 20 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK